Aromatase inhibitors 'eclipse tamoxifen' in younger women

Among patients with early breast cancer undergoing ovarian suppression, aromatase inhibitors cut tumour recurrence by a third, data show

Replacing tamoxifen with an aromatase inhibitor in premenopausal women receiving ovarian suppression therapy significantly decreases the risk of breast cancer recurrence, a meta-analysis shows.

However, use of the agents — including anastrozole, exemestane or letrozole — appeared to have no impact on breast cancer mortality, an international research collaboration has found.

Using individual patient-level data from four randomised trials, the University of Oxford-led